HSD17B3
HSD17B3 (hydroxysteroid 17-beta dehydrogenase 3, also known as SDR12C2) is an endoplasmic reticulum short-chain dehydrogenase/reductase that converts 17-oxosteroids to 17beta-hydroxysteroids. It favours the reduction of androstenedione to testosterone, the key androgen driving male development and function. Browse Assay Genie's current range of HSD17B3 research reagents below, or read on for the biology behind the target.
HSD17B3 catalyses the conversion of 17-oxosteroids to 17beta-hydroxysteroids. Its best-characterised reaction is the reduction of androstenedione to testosterone, and testosterone is the key androgen driving male development and function. The enzyme uses NADPH as cofactor, whereas the two other EDH17B enzymes use NADH. Other androgens, including epiandrosterone, dehydroepiandrosterone, androsterone and androstanedione, are accepted as substrates and reduced at C-17. HSD17B3 can also reduce 11-ketoandrostenedione and 11beta-hydroxyandrostenedione at C-17 to the respective testosterone forms.
The HSD17B3 gene encodes 17-beta-hydroxysteroid dehydrogenase type 3, which belongs to the short-chain dehydrogenase/reductase (SDR) superfamily and to the 17-beta-HSD 3 subfamily. The protein localises to the endoplasmic reticulum. According to the NCBI Gene summary, this isoform of 17 beta-hydroxysteroid dehydrogenase is expressed predominantly in the testis, where it carries out the final step in testosterone formation from androstenedione and preferentially uses NADP as cofactor.
The gene was previously named hydroxysteroid (17-beta) dehydrogenase 3 and carries the alternative symbol SDR12C2. Deficiency of HSD17B3 can result in male pseudohermaphroditism with gynecomastia, which links the enzyme directly to androgen biosynthesis and male sexual differentiation. Mouse and rat orthologs, both named Hsd17b3, are annotated, allowing comparative work in rodent models.
HSD17B3 reduces androstenedione to testosterone, making it a central enzyme for studying how active androgens are generated.
Testosterone drives male development and function, and HSD17B3 deficiency can cause male pseudohermaphroditism with gynecomastia.
Expression is predominantly testicular, so HSD17B3 is relevant to studies of steroid production in the testis.
HSD17B3 uses NADPH and accepts several androgens and 11-oxygenated substrates, supporting work on cofactor use and substrate range among 17-beta-HSDs.
HSD17B3 catalyses the conversion of 17-oxosteroids to 17beta-hydroxysteroids. It favours reduction of androstenedione to testosterone, using NADPH as cofactor. It also reduces several other androgens at C-17, including dehydroepiandrosterone, androsterone and 11-ketoandrostenedione.
HGNC lists the gene as hydroxysteroid 17-beta dehydrogenase 3, previously hydroxysteroid (17-beta) dehydrogenase 3, with the alias SDR12C2. UniProt names the protein 17-beta-hydroxysteroid dehydrogenase type 3, a member of the 17-beta-HSD 3 subfamily of the SDR family.
Yes. Deficiency of HSD17B3 can result in male pseudohermaphroditism with gynecomastia. Orthologs named Hsd17b3 exist in mouse and rat; check the datasheet of any product for its validated reactivity.
Other hydroxysteroid dehydrogenases and steroid-metabolising enzymes from the SDR superfamily with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P37058; product specifications from Assay Genie datasheets.